Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI drug discovery company identifying multi-protein combination therapeutics 4x faster at 90% lower cost; YC S23 $4.5M Boom Capital Series A with in vivo/vitro results competing with Recursion for combination therapy AI.
Olio Labs is a San Francisco-based computational drug discovery company using AI and machine learning to identify multi-protein combination therapeutics for complex diseases — targeting biological pathways where single-target drugs fail because the disease involves multiple protein interactions simultaneously. Founded in 2023 and backed by Y Combinator (S23) with $5 million raised including a $4.5 million Series A led by Boom Capital and Overwater Ventures in March 2025, Olio Labs' combination therapeutics platform has demonstrated in vivo and in vitro superiority over existing market drugs, with a discovery process claimed to be 4x faster and 90% lower cost than traditional drug development approaches.
$2.3B raised at $29.3B valuation; $2B+ ARR (Q1 2026); used by 50%+ of Fortune 500. Dominant commercial AI coding tool; built on VSCode fork with native agent mode. Competing with GitHub Copilot, Windsurf, and Lovable in the vibe-coding wave.
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities directly in the development workflow. The company serves software developers seeking to accelerate coding productivity through AI assistance while maintaining full control and understanding of their code. Cursor delivers value through contextual code suggestions that understand entire codebases, natural language commands to modify code, inline AI chat for explaining complex code, and a familiar VS Code interface that requires minimal learning curve for existing developers.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.